Evidence map›Paper›PMID 41865032›Full record

ArticleBMC pharmacology & toxicology2026

Comparative study of cardio-protective effect of metformin versus dapagliflozin in experimentally induced myocardial infarction in diabetic rats.

Dina Elhantery, Somaia Abdullatif Mokbel, Abdelaziz M Hussein, E M Tayee, Sara El Desouky, Ahmed Mohammed Taha

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dina ElhanteryDepartment of Medical Pharmacology, Faculty of Medicine, Helwan University, Cairo, Egypt. Dina_medhat@med.helwan.edu.eg.
Somaia Abdullatif MokbelDepartment of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Abdelaziz M HusseinDepartment of Medical Physiology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
E M TayeeDepartment of Medical Pharmacology, Faculty of Medicine, Helwan University, Cairo, Egypt.
Sara El DesoukyMedical Experimental Research Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed Mohammed TahaDepartment of Medical Pharmacology, Faculty of Medicine, Helwan University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the potential cardioprotective role of dapagliflozin in comparison to metformin in experimentally- induced myocardial infarction in rats with type 2 diabetes mellitus (T2DM). MATERIALS AND

methodsThis study was comparative study, which was housed at the animal house, Mansoura Experimental Research Center (MERC). Fifty adult male albino rats were included in this study and there were further randomly divided into Group-I: (Normal), Group –II: rats received Streptozotocin (STZ) for induction of type 2 DM. This group was subdivided into (4) equal subgroups as the following: Group –IIa: (DM), Group-IIb: (DM+ISO), Group–IIc: (DM+ISO+Metformin), Group-IId: (DM+ISO+DAPA). The outcomes of the study were measured by ECG recording, serological study which included Interleukin (IL)-10, IL6, and tumor necrosis factor (TNF)-α, troponin, lipid profile and blood glucose and histopathological examination of isolated hearts.

resultsDapagliflozin show better cardioprotective effect than Metformin with lower IL-10, IL-6, TNF, CTNI and Troponin C levels than Metformin with statistically significant difference (p < 0.001*). The percentage of area of edema and degeneration is the lowest in controls followed by DM+ISO+DAPA group then DM+ISO+Metformin group when compared with DM and DM+ISO groups which revealed the cardio protective effect of DAPA and Metformin with inter-groups statistically significant difference (p < 0.001*)

conclusionDapagliflozin has cardioprotective effects against myocardial infarction in type 2 diabetic rats. This effect might be due to its antifibrotic and antiarrhythmic effects. However, Metformin did not show any antifibrotic or anti-arrhythmic effects.

Indexed as

Benzhydryl CompoundsCardiotonic AgentsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2GlucosidesHypoglycemic AgentsMetforminMyocardial InfarctionAnimalsBlood GlucoseMaleMyocardiumRatsTumor Necrosis Factor-alphaBenzhydryl CompoundsBlood GlucoseCardiotonic AgentsdapagliflozinGlucosidesHypoglycemic AgentsMetforminTumor Necrosis Factor-alphaDapagliflozinMetforminMyocardial infarction-isoprenalineType II diabetes mellitus

Identifiers

PMID41865032
PMCPMC13063645

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.